MIMS February prescribing update

New products

Agrippal (inactivated influenza vaccine [surface antigen]) contains the following strains for the 2011 influenza season: A/California/07/2009 (H1N1)-like strain (A/California/07/2009, NYMC X-181); A/Perth/16/2009 (H3N2)-like strain (A/Victoria/210/2009, NYMC X-187); and B/Brisbane/60/2008-like strain (B/Brisbane/60/2008, NYMC BX-35. Agrippal induces humoral antibodies against haemagglutinins, the surface antigens of the virus. These antibodies neutralise influenza viruses and are important in the prevention of natural infections. Agrippal is indicated for the prevention of influenza caused by influenza virus types A and B. Agrippal is contraindicated in those with hypersensitivity to eggs, chicken proteins, kanamycin, neomycin, formaldehyde, cetrimonium bromide (CTAB) or polysorbate 80. Immunisation should be postponed in patients with an acute severe febrile illness (fever > 38.5°C).  The recommended